Trials / Completed
CompletedNCT04262856
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 151 (actual)
- Sponsor
- Arcus Biosciences, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This randomized phase 2 open-label study will evaluate the safety and efficacy of zimberelimab (AB122) monotherapy, domvanalimab (AB154) in combination with zimberelimab, and domvanalimab in combination with zimberelimab and etrumadenant (AB928) in front-line, PD-L1 positive, metastatic non-small cell lung cancer.
Conditions
- Non Small Cell Lung Cancer
- Nonsquamous Non Small Cell Lung Cancer
- Squamous Non Small Cell Lung Cancer
- Lung Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Domvanalimab | Domvanalimab is a humanized monoclonal antibody targeting human TIGIT |
| DRUG | Etrumadenant | Etrumadenant is an A2aR and A2bR antagonist |
| DRUG | Zimberelimab | Zimberelimab is a fully human anti-PD-1 monoclonal antibody |
Timeline
- Start date
- 2020-05-28
- Primary completion
- 2025-06-05
- Completion
- 2025-07-09
- First posted
- 2020-02-10
- Last updated
- 2025-08-26
Locations
44 sites across 7 countries: United States, Australia, Canada, Hong Kong, Singapore, South Korea, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04262856. Inclusion in this directory is not an endorsement.